Evotec SE (EVO)
Bid | 3.49 |
Market Cap | 1.24B |
Revenue (ttm) | 777.33M |
Net Income (ttm) | -155.53M |
EPS (ttm) | -0.52 |
PE Ratio (ttm) | -6.74 |
Forward PE | -46.12 |
Analyst | Hold |
Dividends | n/a |
Ask | 3.52 |
Volume | 4,776 |
Avg. Volume (20D) | 62,798 |
Open | 3.48 |
Previous Close | 3.54 |
Day's Range | 3.46 - 3.50 |
52-Week Range | 2.84 - 5.64 |
Beta | 1.06 |
Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for EVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription

1 month ago · accessnewswire.com
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy ExecutionStrategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Pre...

1 month ago · accessnewswire.com
Evotec SE to announce first half-year results 2025 on 13 August 2025HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim r...

1 month ago · accessnewswire.com
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse SiteHAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...

2 months ago · accessnewswire.com
Evotec SE Adjusts Revenue Guidance while Confirming Profit GuidanceHAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its ...